Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Jean-Philippe

Showing results (61-70 of 83) with videos related to

Pageof 9
Sort By:
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPatricia M Flynn, Mark Mirochnick, David E Shapiro, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmissionJane C Lindsey, Michael D Hughes, Avy Violari, et al.
Plos One|December 10, 2016
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060Charlotte V Hobbs, Erin E Gabriel, Portia Kamthunzi, et al.
The New England Journal of Medicine|June 22, 2012
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected childrenAvy Violari, Jane C Lindsey, Michael D Hughes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) TrialGaerolwe Masheto, Sean S Brummel, Lauren Ziemba, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2025
Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTEDTk Nguyen, Jung-Woo Chae, Lauren Ziemba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young ChildrenEdmund V Capparelli, Gbolahan Ajibola, Kenneth Maswabi, et al.
The Lancet. HIV|September 27, 2025
ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept studyDeborah Persaud, Anne Coletti, Bryan S Nelson, et al.
Pageof 9

Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPatricia M Flynn, Mark Mirochnick, David E Shapiro, et al.
The Pediatric Infectious Disease Journal|September 16, 2014
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmissionJane C Lindsey, Michael D Hughes, Avy Violari, et al.
Plos One|December 10, 2016
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060Charlotte V Hobbs, Erin E Gabriel, Portia Kamthunzi, et al.
The New England Journal of Medicine|June 22, 2012
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected childrenAvy Violari, Jane C Lindsey, Michael D Hughes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) TrialGaerolwe Masheto, Sean S Brummel, Lauren Ziemba, et al.
The Journal of Infectious Diseases|June 22, 2022
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV-Seronegative ChildrenColeen K Cunningham, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|December 7, 2023
HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept studyDeborah Persaud, Yvonne Bryson, Bryan S Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2025
Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTEDTk Nguyen, Jung-Woo Chae, Lauren Ziemba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young ChildrenEdmund V Capparelli, Gbolahan Ajibola, Kenneth Maswabi, et al.
The Lancet. HIV|September 27, 2025
ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept studyDeborah Persaud, Anne Coletti, Bryan S Nelson, et al.
Pageof 9